Drug Innovation
340B
Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Drug Innovation
Why Failure-to-Market Claims Are Preempted Under Federal Law
A California appellate court invented out of whole cloth a new and troubling theory of tort liability. Specifically, the court held that drug companies have a duty to develop and bring to market drugs that are supposedly safer and more effective than another, FDA-approved drug the company sells already. The ...
Book
Read the new book from Sally Pipes “The World’s Medicine Chest”
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. <The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special ...
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Drug Innovation
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Biosimilars
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Blog
Learn about case that could threaten medical innovation
PRI Files Amicus Brief in Key State Supreme Court Case That Could Upend Future Medical Innovation in California
In the case, the plaintiffs filed cases against the Gilead pharmaceutical company over the company’s failure to bring an alternative medication used to treat AIDS, hepatitis, and other diseases to the marketplace called TAF under a speedier timeline, even though TAF and the originally developed medicine called TDF are both ...
Biosimilars
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could have ...
Commentary
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Biosimilars
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Why Failure-to-Market Claims Are Preempted Under Federal Law
A California appellate court invented out of whole cloth a new and troubling theory of tort liability. Specifically, the court held that drug companies have a duty to develop and bring to market drugs that are supposedly safer and more effective than another, FDA-approved drug the company sells already. The ...
Read the new book from Sally Pipes “The World’s Medicine Chest”
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. <The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Learn about case that could threaten medical innovation
PRI Files Amicus Brief in Key State Supreme Court Case That Could Upend Future Medical Innovation in California
In the case, the plaintiffs filed cases against the Gilead pharmaceutical company over the company’s failure to bring an alternative medication used to treat AIDS, hepatitis, and other diseases to the marketplace called TAF under a speedier timeline, even though TAF and the originally developed medicine called TDF are both ...
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could have ...
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
